Biocept, Inc. (BIOC) Receives $2.50 Consensus Price Target from Analysts

Shares of Biocept, Inc. (NASDAQ:BIOC) have earned a consensus rating of “Hold” from the five analysts that are covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation and three have given a buy recommendation to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $2.50.

A number of research analysts have issued reports on BIOC shares. ValuEngine downgraded shares of Biocept from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. Zacks Investment Research upgraded shares of Biocept from a “hold” rating to a “buy” rating and set a $1.75 target price on the stock in a research report on Friday, June 2nd. Finally, Westpark Capital restated an “outperform” rating on shares of Biocept in a research report on Thursday, August 3rd.

A hedge fund recently raised its stake in Biocept stock. Vanguard Group Inc. grew its stake in Biocept, Inc. (NASDAQ:BIOC) by 9.6% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 764,351 shares of the medical research company’s stock after acquiring an additional 66,746 shares during the quarter. Vanguard Group Inc. owned 2.87% of Biocept worth $1,048,000 at the end of the most recent quarter. 6.92% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This news story was originally published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this news story on another site, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be accessed at

Shares of Biocept (BIOC) traded down 0.79% during trading on Friday, hitting $1.25. 172,374 shares of the stock traded hands. The company has a 50 day moving average of $1.28 and a 200-day moving average of $1.56. The company’s market cap is $37.82 million. Biocept has a 1-year low of $0.74 and a 1-year high of $3.39.

Biocept (NASDAQ:BIOC) last issued its quarterly earnings results on Thursday, August 10th. The medical research company reported ($0.21) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.20) by ($0.01). Biocept had a negative return on equity of 550.35% and a negative net margin of 359.48%. The company had revenue of $1.28 million for the quarter, compared to analyst estimates of $1.23 million. On average, equities analysts anticipate that Biocept will post ($0.79) EPS for the current fiscal year.

Biocept Company Profile

Biocept, Inc is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company’s Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample.

Receive News & Ratings for Biocept Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply